NEXEL Co., Ltd. is committed to becoming a world-class biotech company. Its aim is to develop innovative new therapies to help patients and provide tools for researchers to boost their projects. Thus, they will create value for the investors, fellow researchers, and the world to make a better place.  NEXEL is a world leader in iPSC (induced pluripotent stem cell) technology as the first Korean company to license iPS technology and setting a new paradigm in the in vitro toxicity field through successful commercialization of iPS derived cells which mimic actual human functionality. Furthermore, they are investing its expertise into the discovery and development of new drug candidates based on proteins and peptides derivations from stem cell technology.  NEXEL iPSC Derived Cardiomyocytes  NEXEL strives to provide high quality human cardiomyocytes from human induced pluripotent stem (iPS) cells using optimized proprietary protocols. The cardiosight-S is a highly pure and electrophysiologically active population of cells, suitable for all types of experiments in the field of cardiomyocytes. Its priority is to ensure researchers get a reliable product and accelerate the diverse projects they are working on.  Also, its human iPSC derived cardiomyocytes have been validated on multiple platforms and the quality control process […] read more